[ad_1] OIS Podcast Episode #270: KOLs Speak Out on the Future of Gene Therapy https://t.co/nXMnR91Btg via @YouTube [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ModernRetina: @BauschLomb and Clearside Biomedical Inc. announced that the U.S. Food and Drug Administration (@US_FDA) has accepted the… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Just published…Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits | TVST | ARVO Journals https://t.co/py84aPE3Ra
#retina #AMD #maculardegeneration #suprachoroidal #cls-ax
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Just published: https://t.co/WYQcf8TY9n “Suprachoroidal delivery of axitinib, combined with pan-VEGF inhibition activity of axitinib, has the potential to provide additional benefits compared to the current standard of care with intravitreal anti–VEGF-A agents.” #retina #AMD [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …
[ad_1] Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xipere on @EyeWireNews https://t.co/CefpnRcEbg [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.